RESERPINE-HYDRALAZINE COMBINATION THERAPY OF HYPERTENSIVE DISEASE, WITH HYDRALAZINE IN DOSES GENERALLY BELOW THE "TOXIC RANGE"
Authors: R E LEE, A M SELIGMANN, D GOEBEL, L A FULTON, M A CLARK
Journal: Annals of Internal Medicine (1956)

Article1 March 1956RESERPINE-HYDRALAZINE COMBINATION THERAPY OF HYPERTENSIVE DISEASE, WITH HYDRALAZINE IN DOSES GENERALLY BELOW THE "TOXIC RANGE"RICHARD E. LEE, ARTHUR M. SELIGMANN, DAVID GOEBEL, LYMAN A. FULTON, MELVA A. CLARKRICHARD E. LEE, ARTHUR M. SELIGMANN, DAVID GOEBEL, LYMAN A. FULTON, MELVA A. CLARKAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-44-3-456 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAlthough mild and labile hypertension frequently responds to Rauwolfia and its derivatives,1, 2, 3more advanced hypertensive disease usually requires an additional pharmacologic agent.4, 5, 6, 7, 8Hydralazine has proved a useful supplementary drug in many such cases. At the dosage levels employed, however, "toxic" side effects have appeared in many instances.9, 10As many as 12% or more of patients receiving over 300 mg. of hydralazine daily may develop arthralgia and/or a "lupus-like" syndrome.10Other instances of toxicity reported in the literature and presented in summary form in table 1 suggest that high dosage level may be an...Bibliography1. Vakil RJ: Clinical trial of Rauwolfia serpentina in essential hypertension, Brit. Heart J. 11: 350 (Oct.) 1949. CrossrefMedlineGoogle Scholar2. WilkinsJudson RWWE: The use of Rauwolfia serpentina in hypertensive patients, New England J. Med. 248: 48, 1953. CrossrefMedlineGoogle Scholar3. Wilkins RW: Clinical usage of Rauwolfia alkaloids including reserpine (Serpasil), Ann. New York Acad. Sc. 59: 36 (Apr.) 1954. CrossrefMedlineGoogle Scholar4. Wilkins RW: Combinations of drugs in the treatment of essential hypertension, Mississippi Doctor 30: 359 (Apr.) 1953. MedlineGoogle Scholar5. FreisAri EDR: Clinical and experimental effects of reserpine in patients with essential hypertension, Ann. New York Acad. Sc. 59: 45 (Apr.) 1954. CrossrefMedlineGoogle Scholar6. LiversayMoyeaMiller WRJHSI: Treatment of hypertension with Rauwolfia serpentina alone and combined with other drugs, J. A. M. A. 155: 1027, 1954. CrossrefMedlineGoogle Scholar7. DoyleMcQueenSmirk AEEGFH: Treatment of hypertension with reserpine, with reserpine in combination with Pentapyrolidium, and with reserpine in combination with veratrum alkaloids, Circulation 11: 170 (Feb.) 1955. CrossrefMedlineGoogle Scholar8. NaegeleRosemanHoffmanFriedman CFRHCLM: Combined Rauwolfia-hydralazine therapy of hypertensive patients, Circulation 11: 182 (Feb.) 1955. CrossrefMedlineGoogle Scholar9. DustanTaylorCorcoranPage HPRDACIA: Rheumatic and febrile syndrome during prolonged hydralazine treatment, J. A. M. A. 154: 23, 1954. CrossrefMedlineGoogle Scholar10. MullerRastPryorOrgain JCCLWWES: Late systemic complications of hydralazine (Apresoline) therapy, J. A. M. A. 157: 894 (Mar. 12) 1955. CrossrefMedlineGoogle Scholar11. Steele JM: Comparison of simultaneous indirect auscultation and direct (intra-arterial) measurements of arterial pressure in man, J. Mt. Sinai Hosp. 8: 1042, 1941-1942. Google Scholar12. Finnerty FA: The value of Rauwolfia serpentina in the hypertensive patient, Am. J. Med. 17: 629 (Nov.) 1954. CrossrefMedlineGoogle Scholar13. McQueenDoyleSmirk EGAEFH: The circulatory effects of reserpine, Circulation 11: 161 (Feb.) 1955. CrossrefMedlineGoogle Scholar14. Greenblatt RB: Use of reserpine in certain gynecologic disorders, Ann. New York Acad. Sc. 59: 133 (Apr.) 1954. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication October 12, 1955.From the Department of Medicine, Cornell University Medical Center, and the New York Hospital, New York, N. Y.†This study was supported in part by the American Heart Association, New York, N. Y., and by CIBA Pharmaceutical Products, Inc., Summit, New Jersey. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byBlood pressure-lowering efficacy of reserpine for primary hypertensionBlood pressure lowering efficacy of reserpine for primary hypertensionCombination pharmacotherapy in hypertensionCombination drug treatment of hypertension: Have we come full circle?Biological basis of stress-related mortalityDrugs Acting on Arteriolar Smooth Muscle (Vasodilator Drugs)Treatment of Essential Hypertension with Combined Vasodilation and Beta-Adrenergic BlockadeThe clinical pharmacology of antihypertensive drugsHemodynamic Effects of HydralazineA Double Blind Evaluation of the Antihypertensive Effect of Reserpine, Phenobarbital, Hydralazine, Syrosingopine, and Placebo in Ambulatory SubjectsA Comparison of the Side Effects and Antihypertensive Potency of Chlorothiazide and HydrochlorothiazideHypertonieHypertonieTHERAPEUTICALLY "REFRACTORY" HYPERTENSION: CAUSATIVE FACTORS, AND MEDICAL MANAGEMENT WITH CHLOROTHIAZIDE AND OTHER AGENTS*RICHARD E. LEE, ARTHUR W. SELIGMANN, MELVA A. CLARK, NEMAT O. BORHANI, JOHN T. QUEENAN, MAUREEN E. O'BRIENThe Rôle of Reserpine in Essential Hypertension when Used alone or Combined with HydralazineCombined hydrallazine and reserpine in the therapy of hypertensionEffect of Rauwolfa serpentina and Reserpine on the Blood Pressure in Essential HypertensionHypotensive Effect of Reserpine Compared with Phenobarbital and Placebo 1 March 1956Volume 44, Issue 3Page: 456-465KeywordsArthralgiaDrugsHeartHospital medicineHypertensionLongitudinal studiesToxicity ePublished: 1 December 2008 Issue Published: 1 March 1956 PDF downloadLoading ...